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 Abstract
The human placenta, characterized by the processes of passive transport and facilitated diffusion, contains nume-
rous active transport proteins, usually located in the microvilli of the syncytiotrophoblast or in the endothelium of 
the capillaries of the villi. These proteins use either the energy from ATP hydrolysis or other mechanisms resulting, 
among others, from the formation of the maternofetal ion gradient, which facilitates the transfer of various endoge-
nous substances or xenobiotics across the body membranes. The proteins either trigger the efflux of these sub-
stances from the fetal tissues via the placenta into the maternal bloodstream, or conversely, they accumulate them 
in the fetal tissues. Both the placenta and the fetus are equipped with independent systems of enzymes of 1st and 
2nd phase of substrate metabolism, such as CYP450, glucuronyltransferase or sulphatase. 
An active therapy with a wide range of drugs, often at high toxicity levels, either shortly before or during pregnancy, 
has naturally posed a question concerning the degree of impermeability of the placental barrier and how effectively 
it can be crossed, including any possible negative embryotoxic or teratogenic consequences. Such hazards seem 
to be quite real, as many drugs are substrates for ABC transporters. Also the placenta itself, including its structure, 
is subject to vast transformations during pregnancy, which may be observed as the thinning of the barrier separating 
the maternal blood from the fetal one, from 20-30μm in the first trimester of gestation down to 2-4μm in the third 
trimester of gestation.
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 Streszczenie
W łożysku ludzi oprócz transportu biernego oraz dyfuzji ułatwionej zawartych jest wiele aktywnych białek transpor-
towych zazwyczaj zlokalizowanych w mikrokosmkach syncytiotrofoblastu lub w śródbłonkach naczyń włosowatych 
kosmków. Wykorzystują energię z rozpadu ATP lub inne mechanizmy wynikające między innymi z formułującego 
się gradientu jonów pomiędzy płodem i matką sprzyjają przenikaniu przez błony różnorodnych substancji endogen-
nych lub ksenobiotyków. Kreuja albo ich wyrzut z tkanek płodu przez łożysko do krwi matki lub wręcz przeciwnie 
kumulują je w jego tkankach. Samo łożysko i płód dysponuje samodzielnymi układami enzymatycznymi pierwszej 
i drugiej fazy przemian substratów takimi jak: CYP450, glukuronylotransferazy czy sulafatazy. 
Aktywne postępowanie terapeutyczne z wykorzystaniem szerokiej gamy leków niejednokrotnie o wysokim poziomie 
toksyczności w okresie przed ciążowym oraz w ciąży rodzi pytanie na ile bariera łożyskowa jest szczelna oraz na 
ile jest skutecznie pokonywana z możliwymi negatywnymi konsekwencjami o charakterze embriotoksycznym lub 
teratogennym. Groźba wydaje się być całkowicie realna, bowiem wiele leków to substraty dla transporterów ABC. 
Również samo łożysko i jego struktura ulega w trakcie ciąży głębokim przewartościowaniom czego miarą może być 
redukcja dzielącej barierę krew matki od krwi płodu z 20-30μm w pierwszym trymestrze ciąży do 2-4μm w trzecim 
trymestrze ciąży. 
 Słowa kluczowe: łożysko / transport leków / białko oporności wielolekowej / 
    / ciąża / syncytiotrofoblast
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Introduction
Over	the	last	several	decades,	the	consumption	of	medicines	










and	 those	 who	 are	 HIV-positive	 [4].	According	 to	 the	 recent	
estimates,	the	number	of	the	last-mentioned	females	approaches	
to	18-19	million	 in	 the	world	[5].	Also	pregnancy	itself,	 inclu-







or	 by	 long-term	effects	 that	 are	 too	 difficult	 to	 predict.	Active	




in	 the	media.	The	drugs	whose	 consumption	by	women	 short-
ly	 before	 or/and	during	 pregnancy	has	 considerably	 increased,	































a.	 Increasing	 contact	 surface	 of	 the	 placental	 syncytio-





c.	The	 thinning	 /decreasing	diameter/μm	of	 the	barrier	 se-










ta,	 found	 in	 dogs	 and	 cats,	 and	 also,	 from	 the	 epitheliochorial	
placenta,	typical	for	sheep,	swine,	or	horse.	(Table	I).	
Its	structure	is	composed	of	the	fetal	tissue	groups,	forming	




Each	of	 the	cotyledons	fills	up	 the	chorionic	 tree,	which	 is	 the	
consequence	of	the	ramification	of	the	chorionic	trunks	into	the	
so-called	terminal	villi,	the	tertiary	ones.	Some	of	the	branches	
of	 the	chorionic	 trunk	 reach	 the	basal	deciduous	membrane	as	
the	 so-called	 anchoring	 villi.	Thus,	 each	 chorionic	 trunk,	with	






cells	 (forming	 the	 stroma	 of	 the	 villi),	 the	 syncytiotrophoblast	


















the	 cytotrophoblast	 cells,	 and	 considerable	 transformations	 in	
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layers,	 to	 the	 favor	of	other	 functions,	 including	 the	metabolic	








The mechanisms of drug transportation 
in the placenta
In	addition	to	the	earlier-mentioned	active	transporters	from	
ABC	 family,	 the	 placental	 exchange	 is	 effected	 in	 other	ways	
as	well,	including	passive	transport,	facilitated	diffusion,	phago-
cytosis	 and	 pinocytosis.	The	 latter	 two	ways	 are	 of	 secondary	









The	 physical	 diffusion	 does	 not	 require	 energy	 input,	 the	
process	 does	 not	 undergo	 saturation	 or	 competence	 inhibition.	
Drugs	undergoing	this	process	are	those	characterized	by	a	low	
molecular	weight,	good	 solubility	 in	 fats,	 and	 they	are	usually	
non-ionized.	 Drugs	 with	 the	 molecular	 weight	 of	 500	 daltons	
permeate	 though	 the	placenta	only	 in	part,	and	 those	weighing	
above	 1000	 daltons	 do	 this	 with	 extreme	 difficulty	 [11].	 The	





in	 lipids,	 but	 hardly	 permeable	 to	 drugs	 soluble	 in	water	 [11].	
Most	drugs,	being	weak	acids	or	alkali	at	the	physiological	pH,	




to	drugs,	 the	 leading	 role	 is	given	 to	albumins	and	α1	acidous	
glycoprotein.	Albumins	bind	to	drugs	that	are	acidous,	whereas	

















   
       
Table I. Structural and functional features of selected mammalian placentas. 
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inhibitors,	 antineoplastic	 drugs,	 tranquillizers,	 anticonvulsants,	








P-glycoprotein (MDR 1/ ABCC 1)
It	is	one	of	the	most	important	and	earliest-known	transpor-
ters.	This	relatively	large	protein	(170kD),	is	located	exclusive-
ly	 on	 the	 apical	 surfaces	 of	 the	microvilli,	which	 significantly	 
extend	the	substrate	area	within	the	syncytiotrophoblast	(Fig.	2).
It	transports	hydrophobic,	uncharged,	weak	alkaline	substra-
tes	whose	molecular	weight	 varies	 from	 220-1880	Da.,	 in	 the	
fetomaternal	direction	[11].	It	participates	in	the	elimination	of	










or	 teratogenic	activities	of	many	xenobiotics	and	 their	 indirect	
metabolites	[11].


















Figure 1. Schematic representation of bidirectional transport of drugs and their metabolites across the human placenta.
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found	both	 in	 the	 syncytiotrophoblast	 and	 in	 the	 endothelia	of	
the	 capillaries	 of	 the	 villi.	 Some	data	 in	 the	 literature	 seem	 to	
suggest	that	this	pump	propels	medicines	into	both	the	fetal	and	
the	maternal	organisms	[17].	




















Breast cancer resistance protein 
(BRCP/ABCG2)
It	is	also	known	as	mitoxantrone-resistance	protein	or	ABC	















Figure 2. Histological  localization of drug transporters in the terminal villus of the human placenta.   
BCRP: breast cancer-resistance protein; hENT: human equilibrative nucleoside transporter; MCT: monocarboxylate transporter, MDR: multi-drug resistance,  
MRP: multi-drug resistance protein; NET; norepinephrine transporter, OAT: organic anion transporter; OCT: organic cation transporter; OCTN organic cation/carnitine transporter; 
SERT: serotonin transporter (see text for detailed information).
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e 779
P R A C E  P O G L Ñ D O W E
  p o ∏ o˝ni c two 
Włoch S, et al.
Ginekol Pol. 2009, 80, 772-777 
Placental transporters of SLC soluble 
substrates 





β-lactam	 antibiotics,	 and	 antiviral	 nucleoside	 analogues	 [23].	













Organic cation transporters SLC22
OCTN1/SLC22A4	and	OCTN2/SLC22A5	are	located	in	the	
microvilli	of	 the	syncytiotrophoblast.	They	demonstrate	a	high	




Monoamine transporters SLC6A and SLC22A
SERT/SLC6A4	 serotonin	 transporter	 and	 NET/SLC6A2	







fetomaternal	 direction,	 via	 the	 placenta,	 not	 only	monoamines	
but	 also	 amphetamine,	 imipramine,	 clonidine,	 and	 cimetidine.	













hENT1/SLC29A1	 and	 hENT2/SLC29A2	 are	 located	 in	
the	syncytiotrophoblast	cells,	 in	 the	microvilli	and	 in	 the	basal	
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